Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 7958.00p Bid 7952.00p Ask 7960.00p Change 2.96%
Last Updated: 04/12/2020 18:19. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2019

Revenue
£24,384.00m
Operating Profit/Loss
£2,924.00m
Dividend yield (%)
2.70
Total dividend for year
$2.8000
Dividend cover
0.37
P/E Ratio
99.50

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Mr Marc Dunoyer
CFO & Executive Director
Mr Leif Johansson
Non-Executive Chairman
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Deborah DiSanzo
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Professor Genevieve Berger
Non-Executive Director
Mr Graham Chipchase
Senior Independent Non-Executive Director

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,312.29m
Market cap
£104,434.07m

Analyst Views (6)

Strong Buy
 
0%
Buy
 
66.67%
Hold
 
33.33%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
7,958.00p
Bid Price
7,952.00p
Ask Price
7,960.00p
Volume
2,105,470
Change Today
229.00p
% Change Today
2.96%
Open
7,849.00p
Previous Close
7,958.00p
Intraday High
7,963.00p
Intraday Low
7,787.00p
52 Week High
9,320.00p
52 Week Low
6,221.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

AstraZeneca sells cholesterol drug rights for up to $350m 01/12/2020 07:41:14 AstraZeneca's 'Forxiga' gets approval in Japan for heart failure 30/11/2020 07:43:44 Europe close: Stocks give back early gains 23/11/2020 17:23:38 Proof of Covid-19 vaccination may be required for travel, says Qantas 23/11/2020 14:05:10 Monday broker round-up 23/11/2020 13:28:07 AstraZeneca Covid-19 vaccine proves effective 23/11/2020 07:02:24 Unions call for frontline workers to have priority access to Covid-19 vaccine 20/11/2020 08:22:22 AstraZeneca gets US approval for additional Imfinzi dosing option 20/11/2020 07:33:41 Berenberg stays at 'buy' on AstraZeneca, positive on antibody treatment 19/11/2020 11:10:02 AstraZeneca vaccine shows promise among elderly 19/11/2020 09:13:13 Pfizer Covid-19 vaccine more than 94% effective in older adults 18/11/2020 12:09:44 Europe close: Stocks finish week on up note, despite remaining risks 13/11/2020 18:41:23 Rising Covid-19 positivity rates in US may require restrictions in large-population states 13/11/2020 13:54:52 HSBC upgrades AstraZeneca on vaccine newsflow 11/11/2020 11:19:15 UK to have 10m doses of Pfizer/BioNTech Covid-19 vaccine by end-2020, if approved 10/11/2020 11:06:52 AstraZeneca sees positive results from asthma treatment trial 10/11/2020 07:37:11 AstraZeneca's Calquence receives EU approval 09/11/2020 08:38:11 AstraZeneca's Brilinta approved in the US to reduce risk of stroke 06/11/2020 08:07:38 AstraZeneca on track to meet guidance 05/11/2020 07:10:20 Thursday preview: Bank of England, AstraZeneca in focus 04/11/2020 14:45:54 Doctors in England on alert for possible Covid-19 vaccine before Christmas 04/11/2020 11:29:26 AstraZeneca Covid-19 vaccine to be widely distributed by end Q1 2021 - report 02/11/2020 12:32:46 Pfizer, AstraZeneca Covid-19 vaccine reviews accelerated - report 30/10/2020 11:46:37 AstraZeneca sells Atacand rights to Cheplapharm for $400m 30/10/2020 07:23:28 AstraZeneca makes regulatory progress with Enhertu and Forxiga 28/10/2020 07:35:12

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Continuing Operations
Revenue
24,384.00
22,090.00
Operating Profit/Loss
2,924.00
3,387.00
Net Interest
-1,260.00
-1.28
Pre-Tax Profit
1,548.00
1,993.00
Profit After Tax from continuing operations
1,227.00
2,050.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
1,227.00
2,050.00
Attributable to:
Equity Holders of Parent Company
1,335.00
2,155.00
Minority Interests
-108.00
-105.00
Total Dividend Paid
$2.8000
$2.8000
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
103.00c
170.00c
Diluted
103.00c
170.00c
Adjusted
103.00c
170.00c
Dividend per Share
$2.8000
$2.8000

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
8,335.00
7,421.00
Intangible Assets
32,501.00
33,666.00
Investment Properties
n/a
n/a
Investments
1,459.00
922.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
3,519.00
3,051.00
Current Assets
Inventories
3,193.00
2,890.00
Trade & Other Receivables
6,046.00
5,781.00
Cash at Bank & In Hand
5,369.00
4,831.00
Current Asset Investments
n/a
n/a
Other Current Assets
955.00
2,089.00
Other Assets
n/a
n/a
Total Assets
61,377.00
60,651.00

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Current Liabilities
Borrowings
2,010.00
1,754.00
Other Current Liabilities
16,107.00
14,538.00
Total Current Liabilities
18,117.00
16,292.00
Non-Current Liabilities
Borrowings
16,217.00
17,359.00
Provisions
3,331.00
3,671.00
Other Non-Current Liabilities
9,116.00
9,285.00
Total Non-Current Liabilities
28,664.00
30,315.00
Other Liabilities
n/a
n/a
Total Liabilities
46,781.00
46,607.00

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Net Assets
14,596.00
14,044.00

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Share Capital
328.00
317.00
Share Premium Account
7,941.00
4,427.00
Other Reserves
2,046.00
2,041.00
Retained Earnings
2,812.00
5,683.00
Shareholders Funds
13,127.00
12,468.00
Minority Interests/Other Equity
1,469.00
1,576.00
Total Equity
14,596.00
14,044.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
2.70%
3.50%
Dividend cover
0.37
0.61
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 4th December 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.